Recent Updates
Recently added Catalysts
NAGE Positive Sentiment Score: 75/100

Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases

Wednesday, July 8, 2026 1 min read
Key Takeaway: Niagen Bioscience has launched its first drug candidate through NAD Pharmaceuticals Corp., targeting accelerated aging and rare genetic diseases. This initiative emphasizes the role of NAD+, a vital coenzyme involved in energy metabolism and cellular functions. The program aims to develop therapies that leverage NAD+ for treating these conditions.
Price reaction · baseline $3.45 (2026-07-07 close) · hit pre-market · clean, no other NAGE news in the window
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a new pharmaceutical program by Niagen Bioscience.
  • Focus on therapies for accelerated aging and rare genetic diseases.
  • NAD+ is a critical coenzyme with significant health implications.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which

Frequently Asked Questions

What is the focus of Niagen's new pharmaceutical program?

The program focuses on developing therapies for accelerated aging and rare genetic diseases.

What role does NAD+ play in health?

NAD+ is crucial for energy metabolism, DNA repair, and cellular stress responses.

Which subsidiary is launching the drug candidate?

The drug candidate is launched by NAD Pharmaceuticals Corp., a subsidiary of Niagen Bioscience.

What is the significance of the drug candidate launch?

It marks Niagen's entry into pharmaceutical development targeting critical health issues.

Tags: NAGE Viatris Investor Conferences Healthcare NAD Pharmaceuticals accelerated aging rare genetic diseases NAD+ Niagen Bioscience
Last updated: Jul 8, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
~165 mo
Minimal dilution risk